These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Oades RD; Klimke A; Henning U; Rao ML Hum Psychopharmacol; 2002 Jan; 17(1):15-27. PubMed ID: 12404703 [TBL] [Abstract][Full Text] [Related]
27. A neuroendocrine study of supersensitivity in tardive dyskinesia. Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219 [TBL] [Abstract][Full Text] [Related]
28. The dopamine hypothesis of schizophrenia revisited. van Kammen DP Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306 [No Abstract] [Full Text] [Related]
30. [Effects of intrathecal injection of beta-endorphin on endocrine function in man (author's transl)]. Yamaya R Masui; 1981 May; 30(5):445-52. PubMed ID: 6268860 [No Abstract] [Full Text] [Related]
32. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance. Wiesel FA Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610 [TBL] [Abstract][Full Text] [Related]
33. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737 [TBL] [Abstract][Full Text] [Related]
34. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment. Perényi A; Frecska E; Bagdy G; Révai K Acta Psychiatr Scand; 1985 Nov; 72(5):430-5. PubMed ID: 2868608 [TBL] [Abstract][Full Text] [Related]
35. No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia. Naber D; Nedopil N; Eben E Br J Psychiatry; 1984 Jun; 144():651-3. PubMed ID: 6146374 [TBL] [Abstract][Full Text] [Related]
36. Naloxone treatment for five days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist. Naber D; Münch U; Wissmann J; Grosse R; Ritt R; Welter D Acta Psychiatr Scand; 1983 Apr; 67(4):265-71. PubMed ID: 6305111 [No Abstract] [Full Text] [Related]
37. [Endorphins of the gamma type in the treatment of schizophrenic psychoses]. Verhoeven WM; Van Ree JM Acta Psychiatr Belg; 1984; 84(2):160-72. PubMed ID: 6204507 [TBL] [Abstract][Full Text] [Related]
38. Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women. Bjerkenstedt L; Gullberg B; Härnryd C; Sedvall G Arch Psychiatr Nervenkr (1970); 1979; 227(3):181-92. PubMed ID: 94992 [No Abstract] [Full Text] [Related]
39. Variability of response to neuroleptics in schizophrenia: clinical, pharmacologic, and neuroendocrine correlates. Gelder M; Kolakowska T Compr Psychiatry; 1979; 20(5):397-408. PubMed ID: 39704 [No Abstract] [Full Text] [Related]
40. The effects of phenothiazines on endocrine function: II. Effects in men and post-menopausal women. Beumont PJ; Corker CS; Friesen HG; Kolakowska T; Mandelbrote M; Marshall J; Murray MA; Wiles DH Br J Psychiatry; 1974 May; 124(0):420-30. PubMed ID: 4151789 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]